APA (7th ed.) Citation

Casey, R., Dong, W., Brachtlova, T., Abramovitch, A., Giddens, J., Incze, P., . . . Beusechem, V. v. (2021). 954 Clinical results from a phase I dose escalation study in treatment-naïve early stage prostate cancer patients with ORCA-010, a potency enhanced oncolytic replication competent adenovirus. Journal for ImmunoTherapy of Cancer, 9(Suppl 2), A1004.

Chicago Style (17th ed.) Citation

Casey, Richard, Wenliang Dong, Tereza Brachtlova, Allan Abramovitch, Jonathan Giddens, Peter Incze, Kenneth Jansz, and Victor van Beusechem. "954 Clinical Results from a Phase I Dose Escalation Study in Treatment-naïve Early Stage Prostate Cancer Patients with ORCA-010, a Potency Enhanced Oncolytic Replication Competent Adenovirus." Journal for ImmunoTherapy of Cancer 9, no. Suppl 2 (2021): A1004.

MLA (9th ed.) Citation

Casey, Richard, et al. "954 Clinical Results from a Phase I Dose Escalation Study in Treatment-naïve Early Stage Prostate Cancer Patients with ORCA-010, a Potency Enhanced Oncolytic Replication Competent Adenovirus." Journal for ImmunoTherapy of Cancer, vol. 9, no. Suppl 2, 2021, p. A1004.